<DOC>
	<DOCNO>NCT00297232</DOCNO>
	<brief_summary>The primary objective initial treatment period study evaluate safety natalizumab monotherapy evaluate risk hypersensitivity reaction immunogenicity follow re-exposure natalizumab confirm safety switch interferon ( IFN ) , glatiramer acetate , multiple sclerosis ( MS ) therapies natalizumab . The primary objective long-term treatment period study evaluate long-term impact natalizumab monotherapy progression disability measure Expanded Disability Status Scale ( EDSS ) change time .</brief_summary>
	<brief_title>Natalizumab ( Tysabri ) Re-Initiation Dosing</brief_title>
	<detailed_description>Study 101-MS-322 ( NCT00306592 ) conduct evaluate safety natalizumab monotherapy follow re-exposure natalizumab former clinical trial participant Studies C-1801 ( NCT00027300 ) , C-1802 ( NCT00030966 ) , C-1803 ( NCT00097760 ) include subject North America . In parallel conduct study , study ( 101-MS-321 [ NCT00297232 ] ) initiate participant Europe rest world . In addition , 48 week , participant 101-MS-322 ( NCT00306592 ) could enter study 101-MS-321 ( NCT 00297232 ) , consider Long-Term Treatment Period 101-MS-322 ( NCT00306592 ) . The primary purpose primary outcome study identical ; therefore , combine long-term data study present . ( Combined Week 48 data study present 101-MS-322 [ NCT00306592 ] record . )</detailed_description>
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis , Relapsing-Remitting</mesh_term>
	<mesh_term>Natalizumab</mesh_term>
	<criteria>Key Inclusion Criteria MS subject complete Study C1801 ( NCT00027300 ) , C1802 ( NCT00030966 ) , C1803 ( NCT00097760 ) Dosing Suspension Safety Evaluation ( neurological examination magnetic resonance image scan ) participate IMA 04001 ( STARS ) Study Subjects consider Investigator free sign symptom suggestive progressive multifocal leukoencephalopathy willing discontinue remain free concomitant immunosuppressive immunomodulatory treatment ( include IFNbeta glatiramer acetate ) treat natalizumab study . In addition , subject complete 48 week treatment Study 101MS322 ( NCT00306592 ) Canada allow enter study start longterm treatment period ( Week 52 480 ) . Key Exclusion Criteria Considered Investigator immunocompromised History persistent antinatalizumab antibody , base upon test prior natalizumab study History major disease malignancy Discontinued natalizumab previous study due allergic reaction NOTE : Other protocol define Inclusion/Exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2015</verification_date>
	<keyword>Multiple Sclerosis</keyword>
	<keyword>MS</keyword>
</DOC>